# Elraglusib

Source: https://onco.cc/drugs/elraglusib/  
OnCo record `elraglusib` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Elraglusib blocks a kinase that helps pancreatic cancer resist chemotherapy; in a randomised phase 2 it lengthened survival when added to gemcitabine and nab-paclitaxel, and a phase 3 is planned.

## Summary

Actuate Therapeutics developed elraglusib from a series of GSK-3 beta inhibitors. In the Actuate 1801 study, part 3B randomised patients with untreated metastatic pancreatic adenocarcinoma to gemcitabine and nab-paclitaxel with or without elraglusib.

The company reported that adding elraglusib improved overall survival and one-year survival, with manageable added toxicity, mainly visual disturbance and fatigue. The result is from a phase 2 trial and awaits confirmation in a phase 3, which Actuate has said it is planning with regulators.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-17
- Also known as: 9-ING-41
- Code: 9-ING-41
- Modality: Small-molecule GSK-3 beta inhibitor
- Mechanism: Inhibits glycogen synthase kinase 3 beta, a kinase that drives NF-kB survival signalling and chemoresistance in pancreatic cancer and dampens anti-tumour immunity.

## Notes

- Randomised phase 2 (Nature Medicine 2026, 155 against 78 patients, untreated metastatic disease): median overall survival 10.1 against 7.2 months with gemcitabine plus nab-paclitaxel alone (hazard ratio 0.62, 95 percent confidence interval 0.46 to 0.84; p 0.01); one-year survival 44.1 against 22.3 percent; grade 3 or worse neutropenia 52.3 against 30.8 percent, fatigue 16.8 against 5.1 percent; the elraglusib dose was reduced to 9.3 mg/kg during the earlier single-arm phase because it exacerbated chemotherapy toxicity (ESMO Open 2025). A phase 3 is planned.

## Sources

- ClinicalTrials.gov NCT03678883: https://clinicaltrials.gov/study/NCT03678883
- Actuate Therapeutics: elraglusib programme: https://www.actuatetherapeutics.com
- Mahalingam et al., elraglusib and chemotherapy in metastatic pancreatic ductal adenocarcinoma, randomised phase 2 (Nature Medicine 2026): https://doi.org/10.1038/s41591-026-04327-4
- Mahalingam et al., single-arm phase 2 (ESMO Open 2025): https://doi.org/10.1016/j.esmoop.2025.105122

## Connected records

- cancers: [Metastatic pancreatic ductal adenocarcinoma](https://onco.cc/cancers/metastatic-pdac/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- technologies: [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- companies: [Actuate Therapeutics](https://onco.cc/companies/actuate-therapeutics/)
- trials: [Actuate 1801 Part 3B (elraglusib)](https://onco.cc/trials/actuate-1801/)

---
JSON: https://onco.cc/api/v1/entities/elraglusib.json